Literature DB >> 25307752

Dietary influences on tissue concentrations of phytanic acid and AMACR expression in the benign human prostate.

Yachana Kataria1, Margaret Wright, Ryan J Deaton, Erika Enk Rueter, Benjamin A Rybicki, Ann B Moser, Vijayalakshmi Ananthanrayanan, Peter H Gann.   

Abstract

BACKGROUND: Alpha-methylacyl-CoA racemase (AMACR) is an enzyme involved in fatty acid metabolism that is markedly over-expressed in virtually all prostate cancers (PCa), relative to benign tissue. One of AMACR's primary substrates, phytanic acid, is derived predominately from red meat and dairy product consumption. Epidemiological evidence suggests links between dairy/red meat intake, as well as phytanic acid levels, and elevated PCa risk. This study investigates the relationships among dietary intake, serum and tissue concentrations of phytanic acid, and AMACR expression (mRNA and protein) in the histologically benign human prostate.
METHODS: Men undergoing radical prostatectomy for the treatment of localized disease provided a food frequency questionnaire (n = 68), fasting blood (n = 35), benign fresh frozen prostate tissue (n = 26), and formalin-fixed paraffin-embedded (FFPE) sections (n = 67). Serum and tissue phytanic acid concentrations were obtained by gas chromatography-mass spectrometry. We extracted RNA from epithelial cells using laser capture microdissection and quantified mRNA expression of AMACR and other genes involved in the peroxisomal phytanic acid metabolism pathway via qRT-PCR. Immunohistochemistry for AMACR was performed on FFPE sections and subsequently quantified via digital image analysis. Associations between diet, serum, and tissue phytanic acid levels, as well as AMACR and other gene expression levels were assessed by partial Spearman correlation coefficients.
RESULTS: High-fat dairy intake was the strongest predictor of circulating phytanic acid concentrations (r = 0.35, P = 0.04). Tissue phytanic acid concentrations were not associated with any dietary sources and were only weakly correlated with serum levels (r = 0.29, P = 0.15). AMACR gene expression was not associated with serum phytanic acid (r = 0.13, P = 0.47), prostatic phytanic acid concentrations (r = 0.03, P = 0.88), or AMACR protein expression (r = -0.16, P = 0.20).
CONCLUSIONS: Our data underscore the complexity of the relationship between AMACR and its substrates and do not support the unifying hypothesis that excess levels of dietary phytanic acid are responsible for both the overexpression of AMACR in prostate cancer and the potential association between PCa risk and intake of dairy foods and red meat.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  AMACR; biomarker; diet; phytanic acid; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 25307752      PMCID: PMC4778716          DOI: 10.1002/pros.22905

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  37 in total

1.  Evaluation of the odd fatty acids 15:0 and 17:0 in serum and adipose tissue as markers of intake of milk and dairy fat.

Authors:  A Brevik; M B Veierød; C A Drevon; L F Andersen
Journal:  Eur J Clin Nutr       Date:  2005-12       Impact factor: 4.016

2.  Serum levels of phytanic acid are associated with prostate cancer risk.

Authors:  Jianfeng Xu; Todd Thornburg; Aubrey R Turner; Mara Vitolins; Doug Case; John Shadle; Lisa Hinson; Jielin Sun; Wennuan Liu; Baoli Chang; Tamara S Adams; S Lilly Zheng; Frank M Torti
Journal:  Prostate       Date:  2005-05-15       Impact factor: 4.104

Review 3.  Phytanic acid: production from phytol, its breakdown and role in human disease.

Authors:  D M van den Brink; R J A Wanders
Journal:  Cell Mol Life Sci       Date:  2006-08       Impact factor: 9.261

4.  Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.

Authors:  Shan Zha; Sacha Ferdinandusse; Jessica L Hicks; Simone Denis; Thomas A Dunn; Ronald J Wanders; Jun Luo; Angelo M De Marzo; William B Isaacs
Journal:  Prostate       Date:  2005-06-01       Impact factor: 4.104

Review 5.  Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer.

Authors:  Y Liu
Journal:  Prostate Cancer Prostatic Dis       Date:  2006-05-09       Impact factor: 5.554

Review 6.  Phytanic acid, AMACR and prostate cancer risk.

Authors:  Todd Thornburg; Aubrey R Turner; Yong Q Chen; Mara Vitolins; Baoli Chang; Jianfeng Xu
Journal:  Future Oncol       Date:  2006-04       Impact factor: 3.404

7.  Measurement characteristics of the Women's Health Initiative food frequency questionnaire.

Authors:  R E Patterson; A R Kristal; L F Tinker; R A Carter; M P Bolton; T Agurs-Collins
Journal:  Ann Epidemiol       Date:  1999-04       Impact factor: 3.797

8.  Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein.

Authors:  C Wolfrum; P Ellinghaus; M Fobker; U Seedorf; G Assmann; T Börchers; F Spener
Journal:  J Lipid Res       Date:  1999-04       Impact factor: 5.922

9.  Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.

Authors:  Vijayalakshmi Ananthanarayanan; Ryan J Deaton; Ximing J Yang; Michael R Pins; Peter H Gann
Journal:  Prostate       Date:  2005-06-01       Impact factor: 4.104

10.  Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.

Authors:  Ming Zhou; Arul M Chinnaiyan; Celina G Kleer; Peter C Lucas; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2002-07       Impact factor: 6.394

View more
  2 in total

Review 1.  The peroxisome: an update on mysteries 2.0.

Authors:  Markus Islinger; Alfred Voelkl; H Dariush Fahimi; Michael Schrader
Journal:  Histochem Cell Biol       Date:  2018-09-15       Impact factor: 4.304

Review 2.  Phytol and its metabolites phytanic and pristanic acids for risk of cancer: current evidence and future directions.

Authors:  Gerd Bobe; Zhenzhen Zhang; Ryan Kopp; Mark Garzotto; Jackilen Shannon; Yumie Takata
Journal:  Eur J Cancer Prev       Date:  2020-03       Impact factor: 2.164

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.